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Targeting of household air pollution: interpretation of RESPIRE
An estimated 3 million infants and children younger than 
5 years die every year from pneumonia in developing 
countries.1 Exposure to household air pollution emitted 
from biomass fuels has been implicated in about a 
third of these cases.2 Observational and case-control 
studies have reported an association between exposure 
to household air pollution and lower respiratory 
tract infections.3 However, until now, no randomised 
controlled intervention trials had been done in children.
In The Lancet, Kirk R Smith and colleagues of the 
Randomised Exposure Study of Pollution Indoors and 
Respiratory Eff ects (RESPIRE) report a randomised trial 
that aimed to reduce household air pollution and its 
subsequent eff ects on early childhood pneumonia.4 The 
RESPIRE trial, which was undertaken in the Guatemalan 
highlands from 2002–04, introduced chimney 
stoves (planchas) in homes using traditional wood 
fi res for cooking. 534 homes with pregnant women 
or infants younger than 4 months were randomly 
assigned to either planchas or control (traditional 
wood fi res); the primary outcome was the reduction 
of physician-diagnosed pneumonia in children with 
use of standardised criteria. Study participants were 
followed up until 18 months of age, with weekly 
visits by fi eldworkers, and subsequent referral to local 
physicians who were masked to intervention status for 
the assessment and diagnosis of pneumonia.
The scope of the RESPIRE trial is impressive, 
and the public health implications are potentially 
monumental. Substantial evidence already exists 
that the fetus and infants are particularly vulnerable 
to the eff ects of exposure to indoor air pollutants 
because of a combination of their developing lungs, 
high minute ventilation per unit of bodyweight, 
and suboptimum metabolism of many toxins.5 On 
the basis of fi ndings from previous studies, carbon 
monoxide measurements were used as surrogates for 
exposure to ambient fi ne particulate matter (PM2·5).6 
Increased exposure to particulate matter has been 
strongly associated with an increased risk of childhood 
pneumonia.7,8 However, RESPIRE’s primary outcome, 
a reduction in pneumonia, was not met (relative risk 
characteristics, such as a low number of positive lymph 
nodes and ER-positive disease, have the greatest survival 
benefi t from locoregional recurrence prevention.
The data from many thousands of clinical trial patients 
reviewed by the EBCTCG investigators continue to 
provide us with crucially important insights. The data 
reinforce the important role that radiotherapy has in 
management of breast cancer, and the fact that the 
benefi ts of radiation are complementary to the advances 
in both surgery and systemic treatment is particularly 
rewarding. The incremental benefi ts of each component 
of treatment contribute to the ongoing success in 
reduction of breast cancer mortality rates.
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[RR] 0·84, 95% CI 0·63–1·13). Notably, there was 
a signifi cant reduction in severe pneumonia, the 
secondary outcome (0·67, 0·45–0·98). 
How should these mixed results be interpreted? As 
the investigators acknowledge, the study had some 
limitations: it might have been underpowered, and 
fi eldworkers were not masked. Additionally, the data 
suggest that the reduction in household air pollution 
levels achieved by the planchas was insuffi  cient to 
provide a more substantial benefi t. Although carbon 
monoxide concentrations were reduced on average 
by 90% in the cooking area, mean child personal 
exposures were reduced only about 50%, from about 
2·2 ppm to 1·1 ppm. This reduction still corresponds 
to a substantial exposure to PM2·5 (about 80 μg/m³)9 
that has been associated with respiratory morbidity in 
children.10 Furthermore, the investigators noted broad 
overlap in exposure concentrations for intervention 
and control households, suggesting exposure mis-
classifi cation in the intention-to-treat analyses. When 
the data were analysed according to child carbon 
monoxide concentration, there was a signifi cant 
reduction in the RR of all physician-diagnosed 
pneumonia (RR 0·82, 95% CI 0·70–0·98) and severe 
pneumonia (0·72, 0·59–0·92), suggesting substantial 
clinical benefi t associated with increasing reductions 
in exposure.
Additional analyses could have been informative, 
such as adjustment for number of cold seasons and 
consideration of time to initial event that could have 
provided estimates of the deleterious time window of 
exposure. Multiple episodes of pneumonia occurred in 
11% of children. A sensitivity analysis that excluded these 
recurrent infections, arguably not independent events, 
could have allayed concerns about bias and outlier 
eff ects. Because anatomical and epigenetic damages 
after prenatal exposure to household air pollution could 
manifest as disease later in life,11,12 analysis of whether 
the intervention instituted during the prenatal period 
(nearly 50% of cases) conferred greater protection 
against early childhood pneumonia than when instituted 
after birth would be of interest.
In view of these results, are household air pollution 
interventions now known to reduce pneumonia and, in 
particular, severe pneumonia in developing countries? 
Probably so, but only if the intervention achieves a 
substantial reduction in personal exposure. These results 
are far from trivial. They should inspire us to improve 
the interventions further, while continuing to target 
pregnant women and young children, and test them in 
other settings. RESPIRE provides important new data 
that can help to guide much needed remedies for the 
unacceptably high rates of early childhood mortality in 
the resource-poor highlands of Guatemala and many 
other areas worldwide.
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Reporting quality of life in clinical trials: a CONSORT extension
Results for health-related quality of life (HRQoL) from 
clinical trials are increasingly used for clinical decision 
making as well as comparative eff ectiveness, health 
policy, and reimbursement decisions. Research suggests 
that HRQoL information can be used to establish 
treatment preferences because patients value HRQoL 
data and can interpret HRQoL fi ndings accurately.1 
Trials that incorporate HRQoL as an outcome should 
therefore be designed, analysed, and reported well.
We did a systematic review of the literature and 
identifi ed 18 publications with guidelines or standards 
for reporting of HRQoL in randomised controlled trials, 
which draw attention to the need for good quality 
in both trial design and reporting. With regard to 
trial design, examples of key quality criteria include: 
the need to use reliable and valid HRQoL measures 
that are appropriate for the population of interest 
and that include core outcomes agreed by clinicians, 
researchers, and patients;2–5 timing of HRQoL assessment 
that is relevant to clinical interpretation of results; 
minimisation of missing data (since data are often not 
missing randomly, but instead could be linked to other 
clinical outcomes of interest, with those most unwell 
not providing data);6 and use of prespecifi ed statistical 
analyses to avoid multiple statistical testing and selective 
reporting of results.
Given these and other requirements for quality 
standards in clinical trial design, many authors have 
recommended standards for HRQoL reporting so that 
readers of trial reports can ascertain whether quality 
standards have been reached. Such standard criteria have 
included, for example, the provision of a clear rationale for 
the domains of HRQoL assessment (eg, specifi c symptoms 
such as pain, or functions such as activity levels) and the 
corresponding choice of HRQoL instrument, with cited 
evidence of the instrument’s validity and a statement 
about the timing of HRQoL assessments used in the trial. 
Trials should report baseline compliance and the extent of 
subsequent missing data, since reports that omit details 
about the amount of missing data, or report substantial 
missing data, should be interpreted with caution. Type 1 
statistical errors, resulting from multiple statistical testing, 
can be addressed by the requirement that trial protocols 
prespecify the principal HRQoL postulated outcomes, 
and their respective timepoints for analysis and reporting 
in the fi nal trial publication.7 Finally, reporting of HRQoL 
data in a comprehensible, clinically applicable format, 
and in the context of other trial outcomes might better 
promote the use of HRQoL data in practice.8
Despite these existing recommendations, a systematic 
review of 794 randomised trials undertaken between 
2002 and 2008 that reported HRQoL outcomes across 
a range of medical conditions showed that only 56% 
of trials provided a rationale for the selected outcome 
measure, 50% provided an HRQoL hypothesis, 28% 
provided information about missing data, and 36% did 
not discuss the HRQoL fi ndings in the context of the other 
trial outcomes.9 The review noted that when HRQoL data 
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